Duan Fangfang, Song Shanshan, Zhai Hang, Wang Yazhi, Cheng Jun, Yang Song
Division 3, Department of Hepatology Capital Medical University Affiliated Beijing Ditan Hospital Beijing China.
Division 2, Department of Hepatology The Fourth People's Hospital of Qinghai Province Qinghai China.
Health Sci Rep. 2025 Jan 12;8(1):e70257. doi: 10.1002/hsr2.70257. eCollection 2025 Jan.
This study aims to investigate the impact of comorbidity with chronic hepatitis B (CHB) on the survival rates and incidence of liver cancer in patients with alcohol-related liver disease (ARLD).
Patients with ARLD and those with ARLD co-morbid with CHB were included in this study and designated as the ARLD group and the ARLD + HBV group, respectively. Propensity score matching (PSM) was then employed to compare survival rates and liver cancer development between these two groups.
Among the 404 patients, 254 were in the ARLD group and 150 in the ARLD + HBV group. After propensity score matching, each group comprised 67 patients. Initially, the ARLD + HBV group exhibited lower 5-year survival rates compared to the ARLD group (51.3% vs. 70.1%, < 0.001). However, PSM mitigated this difference, with survival rates now comparable (61.2% vs. 60.9%, = 0.390). Notably, the ARLD + HBV group showed a higher incidence of liver-specific mortality after matching (32.6% vs. 6.2%, = 0.018). Furthermore, although a higher proportion of patients in the ARLD + HBV group developed liver cancer post-matching, the difference was not statistically significant compared to the ARLD group (15.7% vs. 9.8%, = 0.170).
Co-morbidity with CHB in ARLD patients elevates the risk of liver-related mortality.
本研究旨在调查合并慢性乙型肝炎（CHB）对酒精性肝病（ARLD）患者生存率和肝癌发病率的影响。
本研究纳入了ARLD患者以及合并CHB的ARLD患者，分别指定为ARLD组和ARLD+HBV组。然后采用倾向评分匹配（PSM）来比较两组之间的生存率和肝癌发生情况。
在404例患者中，ARLD组有254例，ARLD+HBV组有150例。倾向评分匹配后，每组各有67例患者。最初，ARLD+HBV组的5年生存率低于ARLD组（51.3%对70.1%，<0.001）。然而，PSM减轻了这种差异，现在两组生存率相当（61.2%对60.9%，=0.390）。值得注意的是，匹配后ARLD+HBV组的肝脏特异性死亡率更高（32.6%对6.2%，=0.018）。此外，虽然ARLD+HBV组匹配后发生肝癌的患者比例更高，但与ARLD组相比差异无统计学意义（15.7%对9.8%，=0.170）。
ARLD患者合并CHB会增加肝脏相关死亡风险。
